Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christian F. Singer, Dominik Hlauschek, Daniel Egle, Zsuzsanna Bago-Horvath, Georg Pfeiler, Christine Brunner, Christian Peters-Engl, Edgar Petru, Daniel Uwe Reimer, Renate Pusch, Michael Seifert, Petra Pichler, Christoph Suppan, Annette Reiner, Richard Greil, Yen Yen Tan, Rupert Bartsch, Katharina Knoll, Anna Sophia Kermanidis, Michael Gnant
Institutions: Comprehensive Cancer Center Vienna, Austrian Breast & Colorectal Cancer Study Group, Medical University of Vienna, Innsbruck Medical University, Universität Innsbruck, Klinik Hietzing, Karl Landsteiner Society, Medical University of Graz, Ordensklinikum Linz Barmherzige Schwestern, Universitätsklinikum St. Pölten, Karl Landsteiner University of Health Sciences, Paracelsus Medical University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809047